DIY SOS to help teenage boy finally return home after years in hospital
Daniel went to the doctor in October 2022 with flu-like symptoms and a sore throat, and he was later sent to Blackpool Victoria Hospital for tests, including a CT scan.The family were told that Daniel had a mass on his brain that was probably a tumour, a diagnosis that was later confirmed at the Royal Manchester Children's Hospital.He had a stroke during a 12-hour emergency operation to save his life, which left him unresponsive and in intensive care for three months. Daniel, now 16, is currently on a respiratory ward at the Manchester hospital as he requires non-invasive ventilation at night.Mr Flemen said he and his wife Julie had been "living separate lives" for the past three years as he works while she goes to see their son. He told BBC Radio Lancashire: "The travelling to and from Manchester - 50-odd miles each way every week, several times a week - it takes a toll on you.
Daniel, who needs hoists and help with all aspects of his personal care, and is fed via a naso-gastric tube, has been making small improvements in recent months.DIY SOS is a long-running TV series that features a team of builders and volunteers coming together to help families in need by renovating their homes. Mr Flemen said the DIY SOS team have a "huge job" converting the house for his return. He said: "Extensions are required, more accommodation for the family, landscaping to make the drive, the front and the rear of the house accessible."These are all things that you never really think about until you've got a wheelchair and a member of the family in that position who needs that additional space and help."Mr Flemen said his son had "started to move his arm and he's been playing Connect Four very badly"."And he's now started to say the odd word. The first words he said to his mum were 'I love you'."
Listen to the best of BBC Radio Lancashire on Sounds and follow BBC Lancashire on Facebook, X and Instagram. You can also send story ideas via Whatsapp to 0808 100 2230.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
9 minutes ago
- The Independent
Mounjaro weight-loss drug price to almost triple in UK after Trump complaint
The price of popular weight-loss jab Mounjaro will nearly triple after the US -owned company equalised costs in markets across the globe. A month's supply of the highest doses of the ' King Kong ' of weight loss medicine will rise from £122 to £330 - an increase of 170 per cent. At least 500,000 people in the UK take either Mounjaro or Wegovy, another weight loss jab, via prescriptions from private online pharmacies, according to retailers. In June, the NHS offered Mounjaro to obese patients after health experts calculated from NHS England data that there were 97,500 patients who would benefit from the treatment. Mounjaro's owner Eli Lily said it would not raise the price paid by the NHS, and it was working with private healthcare providers to maintain access to the jab. The move reflects how the pharmaceutical industry is navigating policy changes in the US, by far its most lucrative market. It comes after Donald Trump's administration complained about 'foreign freeloaders' who rely on the US to pay more for medicine. Last month, he reportedly wrote to the leaders of pharmaceutical companies, including Eli Lilly, asking them to match US prescription drug prices with what is paid overseas. The US pays more for prescription drugs than any other country, often nearly three times as much as other developed nations. Eli Lilly launched Mounjaro in the UK in February last year, while rival Novo Nordisk's Wegovy treatment has been available in the country since September 2023. The company said when it launched Mounjaro in the UK, it agreed to a list price " significantly below" that in its three other European markets to prevent delays in availability through the NHS. 'We are now aligning the list price more consistently,' a spokesperson said. In the UK, the NHS was told to offer Mounjaro to patients with a BMI of over 40 and at least four clinical conditions related to their weight, such as heart disease or type 2 diabetes. Over the next three years, about 240,000 patients are expected to be eligible for the treatment. It came after the National Institute for Health and Care Excellence (Nice) warned many individuals might regain weight if not adequately supported after ceasing treatment. It stressed that those coming off the drugs should be offered "structured advice and follow-up support" to mitigate weight gain. This guidance applies to individuals receiving these treatments through the NHS. The new 'quality standard' from Nice said NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. Weight-loss injections, also known as GLP-1 receptor agonists, work by mimicking the natural hormone which regulates blood sugar, appetite and digestion.
BBC News
4 hours ago
- BBC News
Government turns to TikTokers to advise on cosmetic surgery abroad
The government is partnering with TikTok influencers to warn people about the risks of travelling abroad for cosmetic growing concern over the rise in Britons seeking overseas treatments such as hair implants and dental work, often lured by lower costs and shorter waiting content creators will urge viewers to talk to a UK doctor first, take out travel insurance and avoid package holidays that include move is part of a wider government campaign to curb so-called medical tourism, as well as tighten regulations for cosmetic practitioners in England. When it comes to cosmetic surgery abroad, the lowest price can come at the highest cost, the campaign aims to raise awareness of the risks, protect patients and avoid the NHS paying to fix botched influencers like Doc Tally and Midwife Marley - who have 240,000 and 38,000 followers on TikTok respectively - will produce videos offering guidance on how to make trips as safe as possible. They will include a checklist to consider before booking a influencers like Doc Tally and Midwife Marley - who have 240,000 and 38,000 followers on TikTok respectively - will produce videos giving advice on how to make trips as safe as will also provide followers with a check list to go through before considering booking a procedure minister Karin Smyth warned that "too many people are being left with life-altering injuries after going abroad for medical procedures, without access to proper advice or safeguards."She said the partnership with TikTok would help people "make safer and more informed choices before they go under the knife – wherever that may be." Things to check before you book:Do thorough research about the procedureCheck the clinic's regulation and the surgeon's credentialsKnow the full cost and understand the aftercareAsk the vital question - if it goes wrong, who will fix it? When cosmetic procedures go wrong, the consequences can be devastating for years ago, Leah Mattson travelled to İzmir in Turkey to have gastric sleeve the surgery was initially successful and helped her lose weight, last year the 27-year-old returned to the same company to remove excess time, the procedure left her with a lopsided belly button, deep scarring on her arms and stomach area that she says left her feeling seeing the results of her surgery, Leah said she burst into tears."I just wanted to cry and I feel like I actually disliked my body more than when I was overweight."Leah found the clinic on social media and was encouraged by other people's positive experiences with similar surgeries."On apps like Instagram and TikTok, you search for weight-loss surgery and see the majority of people go to Turkey," she explained."I was thinking well all these people have had great experiences so I'm going to go."I just trusted them because I thought well if they're okay then I'll be okay and I didn't really pay much attention to the horror stories," she added."I didn't think it would ever happen to me."Leah now documents her experience on social media, using her platform to inform others about the risks involved in similar clinic which performed Leah's surgery in Turkey could not be reached for comment, but they previously issued a statement saying "plastic surgery isn't straight-forward and unfortunately some health issues or complications cannot be anticipated". Experts are urging people to think beyond the slick brochures and marketing, and to consider clinical standards, complication risks, and language Foreign Office will also provide more detailed travel advice for those considering going overseas for such Office Minister Stephen Doughty said: "If you choose to travel abroad for medical treatment, it is vital you do your research and are fully aware of the risks involved.""We urge anyone considering a medical procedure abroad to review our travel advice, relevant guidance from the NHS and other professional bodies, and research foreign providers thoroughly to ensure they meet the highest standard of care.""Informed choices today can help avoid serious complications tomorrow."Ali Law, TikTok's UK public policy lead, said the platform was "committed" to helping users find "information from trusted sources when searching for topics related to physical and mental health." Earlier this month, ministers outlined plans to reduce unsafe cosmetic treatments in the new rules, only "suitably qualified" and regulated health workers will be allowed to deliver high-risk procedures such as Brazilian butt offering lower-risk procedures such as Botox and fillers will need a licence, and age limits will be introduced to stop children from copying dangerous beauty trends seen on social media.
The Independent
5 hours ago
- The Independent
Boy with fragile skin disorder given hope after new treatment
A boy with a rare skin condition which can cause damage with even the smallest amount of friction has been given hope after taking part in a trial for the first potential treatment for the genetic disorder. Gabrielius Misurenkovas, 12, from east London, was diagnosed with an inflammatory disease called recessive dystrophic epidermolysis bullosa (RDEB) when he was a baby. Many symptoms of the painful condition have been alleviated thanks to a new trial in which he received certain stem cells via an intravenous drip. The rare genetic disease is severely debilitating. People with the condition have extremely fragile skin which is easily damaged, leading to blistering, deep wounds and scarring. About 150 children in the UK are affected by RDEB, which is painful and causes itchiness. With no disease-modifying treatment available, patients and their families manage symptoms by dressing wounds and applying eye ointments. Over time, the condition can lead to severe complications and many patients with the condition develop a type of skin cancer called squamous cell carcinoma when they are young adults – this is the most common cause of death for RDEB patients. Gabrielius has been under the care of medics at the world-renowned children's hospital Great Ormond Street (GOSH) since he was a baby. He said he jumped at the chance to join the clinical trial when it was suggested by his doctors. 'I wanted to take part in the trial as I was excited to see if it could help improve my condition and so I could do more of the things I enjoy, like playing football and spending time with my friends,' he said. The youngster, who can speak three languages and is a big fan of footballer Lionel Messi, needed his bandages changing three times a day, or more if he was injured. His mother, Jolita Cekaviciene, said: 'Gabrielius did really well on the trial. 'His wounds healed quicker, and his skin was less red and inflamed. 'His skin was also less itchy which also reduced him scratching. 'His sleep was also less disturbed as he didn't need to have his special wound dressings changed as often, so this was a great benefit.' She said Gabrielius has managed to do a few things that he was not able to before the treatment, including taking part in some sports at school, riding his bike in the park on the grass, and being able to play football with his friends, with a soft ball. Ms Cekaviciene said the trial has given her son more freedom than before, but he still needs to be careful in any activity to avoid falling over or bumps. Gabrielius was referred to GOSH as a baby after medics spotted a wound when he was born, and he was diagnosed with RDEB when he was two weeks old. Ms Cekaviciene said: 'The first two years were really hard as you had to watch him constantly – even rubbing his eyes could cause painful blistering. 'He couldn't even tell us how much pain he was in or where he was hurting.' RDEB is a genetic condition which is caused by a fault in the gene that makes a protein which holds layers of skin together – collagen VII. Medics wanted to assess whether regular infusions with mesenchymal stromal cells (MSC) improved symptoms for children with the condition, after studies suggested that MSC treatments could promote wound healing, reduce inflammation and stimulate tissue regeneration. In the trial, funded by NHS England, the National Institute for Health and Care Research and the charity Cure EB, children were given a treatment called CORDStrom, manufactured by INmuneBio. Gabrielius is one of 30 children who took part in the new clinical trial at GOSH and Birmingham Children's Hospital. Patients would go into hospital and have a drip which delivers the cells over 10 to 15 minutes. In the study patients were split into two groups, about half were given the treatment, which is made from umbilical cord tissue, as an infusion, twice over two weeks. The other half were given a placebo, also known as a dummy drug. They then had a nine-month gap, known as a wash-out period, where the group that were initially given the dummy drug were given the treatment, while the group that received therapy first were given a dummy drug. The study, published in the journal eClinicalMedicine, reported a positive outcome of the treatment. The largest effects were in children under the age of 10, and in the children with intermediate type of RDEB. Families involved in the study reported a positive impact on daily life and well-being, with a reduction in both pain and itching. The treatment was said to be well tolerated by the children. INmuneBio have agreed to provide CORDStrom free of charge for a year for all children who took part in the trial, so researchers can continue to study them, and patients are expected to get two infusions of the treatment every four months. The company is seeking regulatory approval for the treatment so it can be approved for use in the UK and other countries. Chief investigator of the study, Dr Anna Martinez, paediatric dermatologist at GOSH, said: 'Our study has demonstrated that CORDStrom was safe and can help reduce disease activity in some patients with RDEB. 'Administering the treatment early and at regular intervals appears to reduce itch and improve wound healing, which over time we hope will reduce inflammation, modify the condition and may reduce over time the future risk of squamous cell carcinoma. 'It's fantastic to see how the patients, like Gabrielius, had improvements in their symptoms and their quality of life.' She added: 'The 12-month open label study will allow us to collect more data to hopefully show an increased benefit from treatments administered in children and young people with RDEB, to continue research in support of the treatment being rolled out more widely.' Sharmila Collins, founder trustee of Cure EB, said: 'Since funding the first trial and by contributing to Mission EB we have been working towards bringing MSC infusions forward for all children in the UK with RDEB. 'We hope these cells will become part of routine clinical care to alleviate the significant suffering of children with this condition.'
